**IMPORTANCE** Plasma phosphorylated tau at threonine 181 (p-tau181) has been proposed as an easily accessible biomarker for the detection of Alzheimer disease (AD) pathology, but its ability to monitor disease progression in AD remains unclear.

**OBJECTIVE** To study the potential of longitudinal plasma p-tau181 measures for assessing neurodegeneration progression and cognitive decline in AD in comparison to plasma neurofilament light chain (NFL), a disease-nonspecific marker of neuronal injury.

**DESIGN, SETTING, AND PARTICIPANTS** This longitudinal cohort study included data from the Alzheimer's Disease Neuroimaging Initiative from February 1, 2007, to June 6, 2016. Follow-up blood sampling was performed for up to 8 years. Plasma p-tau181 measurements were performed in 2020. This was a multicentric observational study of 1113 participants, including cognitively unimpaired participants as well as patients with cognitive impairment (mild cognitive impairment and AD dementia). Participants were eligible for inclusion if they had available plasma p-tau181 and NFL measurements and at least 1 fluorine-18-labeled fluorodeoxyglucose (FDG) positron emission tomography (PET) or structural magnetic resonance imaging scan performed at the same study visit. Exclusion criteria included any significant neurologic disorder other than suspected AD; presence of infection, infarction, or multiple lacunes as detected by magnetic resonance imaging; and any significant systemic condition that could lead to difficulty complying with the protocol.

**EXPOSURES** Plasma p-tau181 and NFL measured with single-molecule array technology.

**MAIN OUTCOMES AND MEASURES** Longitudinal imaging markers of neurodegeneration (FDG PET and structural magnetic resonance imaging) and cognitive test scores (Preclinical Alzheimer Cognitive Composite and Alzheimer Disease Assessment Scale–Cognitive Subscale with 13 tasks). Data were analyzed from June 20 to August 15, 2020.

**RESULTS** Of the 1113 participants (mean [SD] age, 74.0 [7.6] years; 600 men [53.9%]; 992 non-Hispanic White participants [89.1%]), a total of 378 individuals (34.0%) were cognitively unimpaired (CU) and 735 participants (66.0%) were cognitively impaired (CImp). Of the CImp group, 537 (73.1%) had mild cognitive impairment, and 198 (26.9%) had AD dementia. Longitudinal changes of plasma p-tau181 were associated with cognitive decline (CU: \( r = -0.24, P < .001 \); CImp: \( r = 0.34, P < .001 \)) and a prospective decrease in glucose metabolism (CU: \( r = -0.05, P = .48 \); CImp: \( r = -0.27, P < .001 \)) and gray matter volume (CU: \( r = -0.19, P < .001 \); CImp: \( r = -0.31, P < .001 \)) in highly AD-characteristic brain regions. These associations were restricted to amyloid-β–positive individuals. Both plasma p-tau181 and NFL were independently associated with cognition and neurodegeneration in brain regions typically affected in AD. However, NFL was also associated with neurodegeneration in brain regions exceeding this AD-typical spatial pattern in amyloid-β–negative participants. Mediation analyses found that approximately 25% to 45% of plasma p-tau181 outcomes on cognition measures were mediated by the neuroimaging-derived markers of neurodegeneration, suggesting links between plasma p-tau181 and cognition independent of these measures.

**CONCLUSIONS AND RELEVANCE** Study findings suggest that plasma p-tau181 was an accessible and scalable marker for predicting and monitoring neurodegeneration and cognitive decline and was, unlike plasma NFL, AD specific. The study findings suggest implications for the use of plasma biomarkers as measures to monitor AD progression in clinical practice and treatment trials.
Alzheimer disease (AD) is a neurodegenerative disorder characterized by the accumulation of amyloid-β (Aβ) plaques and neurofibrillary tangles of hyperphosphorylated tau in the brain. These neuropathologic changes are believed to take part in a cascade of events that result in a characteristic neurodegeneration pattern followed by progressive cognitive impairment. Tracking neurodegenerative changes in vivo is important for monitoring AD progression. Current positron emission tomography (PET) and cerebrospinal fluid biomarkers enable the detection of Aβ and tau pathology, but the generalized use of these biomarkers is currently limited by their costs, availability, and invasiveness.

Recent evidence suggests that blood-based biomarkers might be useful to detect AD pathology, potentially promoting the widespread use of biomarkers in the diagnostic workup of AD and clinical trial screening. Among candidate disease-specific biomarkers in blood, plasma phosphorylated tau at threonine 181 (p-tau181) has shown promise as a marker of disease status. However, the potential of plasma p-tau181 as a marker of disease progression remains largely unexplored. Specifically, it remains unclear how baseline and longitudinal plasma p-tau181 is associated with progressive AD-specific neurodegeneration; whether plasma p-tau181 provides complementary information to non-disease-specific plasma biomarkers of neurodegeneration, such as neurofilament light chain (NFL); and how imaging neurodegeneration markers mediate the association between plasma p-tau181 and cognitive decline.

In this study, we hypothesized that both baseline and longitudinal plasma p-tau181 levels associate with progressive AD-related neurodegeneration, which may mediate the associations between p-tau181 and cognitive decline. To test this hypothesis, we investigated longitudinal associations between plasma p-tau181 and established imaging markers of regional neurodegeneration on fluorine 18-labeled [18F]fluorodeoxyglucose (FDG) PET and structural magnetic resonance imaging (MRI), as well as relationships with cognitive performance, in more than 1000 individuals from the Alzheimer’s Disease Neuroimaging Initiative (ADNI). In addition, we explored whether plasma p-tau181 provides complementary information to plasma NFL in forecasting and tracking AD-related neurodegeneration and cognitive decline.

**Methods**

**Study Design**

Data used in this cohort study were obtained from the ADNI database from February 1, 2007, to June 6, 2016 (eMethods in Supplement 1). In this study, we included all cognitively unimpaired (CU) and cognitively impaired (Cimp) participants, including those with mild cognitive impairment and AD dementia, from the ADNI Grand Opportunity/ADNI2 study with available plasma p-tau181 and NFL data and at least 1 FDG PET scan or structural T1 MRI performed at the same study visit (n = 1113). In addition, 1048 participants of the study sample also underwent PET imaging with the Aβ-sensitive tracer [18F]florbetapir. Demographic characteristics of study participants are presented in the Table. Further details of baseline and follow-up assessments are provided in the eMethods in Supplement 1. Inclusion criteria for the different diagnostic categories in the ADNI cohort have been described previously. All participants provided written informed consent approved by the institutional review board of each ADNI participating institution. This study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline.

**Blood Biomarkers**

Blood sampling and processing were carried out in accordance with the ADNI protocol and analyzed at the Clinical Neurochemistry Laboratory, University of Gothenburg in Mölndal, Sweden. Plasma p-tau181 concentration was measured using a novel assay developed in-house on the single-molecule array HD-X (Simoa; Quanterix Corporation) instrument, as described previously. Plasma NFL concentration was also measured using Simoa, as previously described. All blood samples were analyzed in a single batch for each measure. We identified 4 outliers for plasma p-tau181 values and 1 for NFL (0.4%), which were excluded from subsequent analyses (eFigure 1 in Supplement 1).

**Neuroimaging**

Acquisition protocols and preprocessing steps in ADNI for FDG PET and structural MRI are described in detail elsewhere and have been summarized in the eMethods in Supplement 1. Our in-house processing pipeline for FDG PET and structural MRI, as well as details of the methods for voxel-wise and region-of-interest (ROI) analyses, are also detailed in the eMethods in Supplement 1. With FDG PET, we measured AD-typical glucose hypometabolism as the average standardized uptake value ratio (SUVR), using the pons as the reference region, in a previously defined Meta-ROI in Montreal Neurological Institute space that recapitulates regions of typical hypometabolism (angular gyrus, posterior cingulate, and inferior temporal gyrus) in AD. Structural T1-weighted MRI
Cognitive Assessments

In CU individuals, global cognitive performance was assessed using a cognitive composite measure specifically designed for detecting early cognitive changes in clinical trials involving CU individuals with evidence of AD pathology, the Preclinical Alzheimer Cognitive Composite (PACC), adapted for the available tests in ADNI. Lower PACC scores represent poorer cognitive performance. In Clmp participants, the Alzheimer Disease Assessment Scale–Cognitive Subscale with 13 tasks (ADAS-Cog 13) was used to assess cognitive impairment severity. Higher ADAS-Cog 13 scores represent poorer cognitive performance.

Statistical Analysis

Individual rates of change in plasma biomarker levels as well as in imaging measures (at the voxel and ROI levels) were estimated using linear mixed models with participant-specific intercepts and slopes predicting biomarker levels over time.

We investigated the associations between (I) baseline plasma biomarker levels and longitudinal change in hypometabolism, atrophy, and cognition and (2) longitudinal plasma biomarker changes and longitudinal hypometabolism, atrophy, and cognitive change. Analyses of the associations between baseline plasma biomarkers and baseline neurodegeneration are provided in the eAppendix and eFigures 2, 3, 4, 5, 6, and 7 in Supplement 1. For each analysis, the following steps were conducted: first, we fitted linear regressions separately for CU and Clmp individuals, adjusted for age and sex (as well as field strength and total intracranial volume for atrophy measures) using voxel or ROI-level imaging-based neurodegeneration markers as the dependent variable and plasma p-tau181 and NfL, respectively, as the independent variable. Second, we studied the independent contributions of each plasma biomarker to hypometabolism or atrophy in the previously defined AD-specific ROIs. For this, we used both plasma p-tau181 and NfL as independent variables in linear models adjusted for the same covariates as described previously, and we compared the corresponding standardized β coefficients by computing 95% CIs derived using a 2000-repetition bootstrap procedure. Effect sizes were computed as partial correlation coefficients (r). These analyses were repeated substituting neurodegeneration markers as response variables by cognitive measures and adjusted for age, sex, and years of education. Additionally, we performed mediation analyses to investigate how imaging neurodegeneration markers influenced the association between plasma p-tau181 and cognition. Finally, we investigated how plasma biomarkers correlated with imaging-based neurodegeneration markers and cognition among participants stratified by cognitive status (CU or Clmp) and APOE status (positive, + or negative, −) according to a previously defined cut point of 1.11 [18F]florbetapir SUVR (using the whole cerebellum as reference region) for ADNI. All statistical analyses were conducted from June 2 to August 15, 2020, using MatLab 2018a (The MathWorks Inc). All tests were 2-sided. Significance level was set at P < .05. No corrections for multiple comparisons were carried out except for voxelwise analyses, following recommendations from the statistical literature that discourage the use of such procedures for hypothesis-driven studies with a limited number of planned comparisons.

Table. Cohort Characteristics

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Cognitively unimpaired (n = 374)</th>
<th>Cognitively impaired (n = 734)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, mean (SD), y</td>
<td>74.8 (6.6)</td>
<td>73.6 (8)</td>
</tr>
<tr>
<td>Sex, men/women, No. (%)</td>
<td>176/198</td>
<td>421/312</td>
</tr>
<tr>
<td>Race/ethnicity, non-Hispanic White, No. (%)</td>
<td>323 (86)</td>
<td>664 (90)</td>
</tr>
<tr>
<td>APOE e4 carriers, No. (%)</td>
<td>108 (29)</td>
<td>376 (51)</td>
</tr>
<tr>
<td>MCI/AD</td>
<td>NA</td>
<td>536/198</td>
</tr>
<tr>
<td>APOE ε4-positive, No. (%)</td>
<td>113 (32)</td>
<td>441 (65)</td>
</tr>
<tr>
<td>Plasma p-tau181, median (range), pg/mL</td>
<td>13.3 (0.4 to 72.3)</td>
<td>18.4 (1.2 to 69.6)</td>
</tr>
<tr>
<td>Plasma NfL, median (range), pg/mL</td>
<td>33.3 (8.0 to 169.0)</td>
<td>37.9 (6.4 to 198.5)</td>
</tr>
<tr>
<td>Meta-ROI glucose metabolism, FDG PET SUVR, mean (SD)</td>
<td>1.57 (0.14)</td>
<td>1.47 (0.18)</td>
</tr>
<tr>
<td>AD-signature ROI volume, mean (SD), cm³</td>
<td>31.4 (3.2)</td>
<td>29.8 (4.2)</td>
</tr>
<tr>
<td>PACC, mean (SD)</td>
<td>0.0 (2.62)</td>
<td>NA</td>
</tr>
<tr>
<td>ADAS-Cog 13, mean (SD)</td>
<td>NA</td>
<td>19.0 (10.5)</td>
</tr>
</tbody>
</table>

Follow-up characteristics

| Plasma p-tau181 Annual change, mean (SD), pg/mL/y | 0.34 (0.39) | 0.49 (0.37) |
| Median follow-up, y | 2.1 | 3.0 |
| Plasma NfL Annual change, mean (SD), pg/mL/y | 1.9 (1.8) | 2.6 (2.5) |
| Median follow-up, y | 2.1 | 3.0 |
| AD-signature ROI volume Annual change, mean (SD), cm³/y | −0.016 (0.009) | −0.019 (0.014) |
| Median follow-up, y | 2.0 | 2.0 |
| PACC Annual change, mean (SD) | −0.20 (0.26) | NA |
| Median follow-up, y | 6.0 | NA |
| ADAS-Cog 13 Annual change, mean (SD) | NA | 1.9 (1.8) |

Abbreviations: Aβ, amyloid-β; AD, Alzheimer disease; ADAS-Cog 13, Alzheimer Disease Assessment Scale–Cognitive Subscale with 13 tasks; APOE, apolipoprotein E; FDG, fluorine 18-labeled fluorodeoxyglucose; MCI, mild cognitive impairment; NA, not applicable; NfL, neurofilament light chain; PACC, Preclinical Alzheimer Cognitive Composite; p-tau181, phosphorylated tau at threonine 181; PET, positron emission tomography; ROI, region of interest; SUVR, standardized uptake value ratio.

* The demographic characteristics of the outlier cases are not reported in this table.

b The ε4+ indicates the proportion of individuals who carry the APOE e4 allele.

* Assessed in a subset of 348 participants.

d Assessed in a subset of 695 participants.

scans were used to measure gray matter volume of a previously defined AD-signature ROI composed of entorhinal, fusiform, inferior temporal, and middle temporal cortices. We also analyzed gray matter volume in a hippocampus ROI as another commonly used structural MRI measure of AD-related neurodegeneration (eTable in Supplement 1).
Results

Baseline Plasma P-Tau181 Predicts Longitudinal Neurodegeneration and Cognitive Decline

Of the 1113 participants (mean [SD] age, 74.0 [7.6] years; 600 men [53.9%]; and 992 non-Hispanic White participants [89.1%]), a total of 378 individuals (34.0%) were CU and 735 participants (66.0%) were Clmp. Of the Clmp group, 537 (73.1%) had mild cognitive impairment, and 198 (26.9%) had AD dementia. We first investigated how baseline plasma p-tau181 levels would predict future neurodegeneration progression. Higher plasma p-tau181 levels were associated with faster longitudinal progression of hypometabolism and atrophy among Clmp individuals in AD-vulnerable areas (FDG PET longitudinal progression of hypometabolism and atrophy in AD-vulnerable regions in Aβ+ participants (FDG PET SUVR change: Aβ+ CU, r = −0.24, P = .08; Aβ+ Clmp, r = −0.23, P = .002; gray matter volume change: Aβ+ CU, r = −0.23, P = .02; Aβ+ Clmp, r = −0.13, P = .01) (Figure 15 in Supplement 1). In line with these results, plasma NFL was also associated with cognitive decline in Aβ− Clmp (r = 0.23, P < .001) and Aβ+ Clmp (r = 0.25, P < .001) participants, but not in any of the CU groups.

Plasma P-Tau181 Changes Parallel Longitudinal Neurodegeneration and Cognitive Decline

We then investigated whether longitudinal increases of plasma p-tau181 accompanied longitudinal neurodegeneration in AD-typical regions. Plasma p-tau181 changes were associated with a decrease in glucose metabolism and an increase in atrophy among Clmp participants, although significant associations with progressive neurodegeneration were also found in CU individuals (FDG PET SUVR change: Clmp, r = −0.27, P < .001; gray matter volume change: CU, r = −0.19, P < .001; Clmp, r = −0.31, P < .001) (Figure 3), particularly with respect to atrophy progression. The spatial associations suggested a high correspondence with AD-typical neurodegeneration patterns, although in the CU group, the pattern was more diffuse and also involved frontal areas. Plasma NFL changes were also significantly associated with progressive neurodegeneration in AD-typical areas (FDG PET SUVR change: CU, r = −0.20, P = .008; Clmp, r = −0.27, P < .001; gray matter volume change: CU, r = −0.11, P = .05; Clmp, r = −0.26, P < .001); however, the spatial pattern also involved other frontoparietal regions less characteristic of AD-typical neurodegeneration (Figure 3A and B). Figure 16 in Supplement 1 shows the spatial overlap between plasma p-tau181 and NFL association maps. In multivariable analyses, changes of both plasma biomarkers were independently associated with progression of imaging-derived neurodegeneration markers (Figure 17 in Supplement 1).

Similar to the associations with progressive neurodegeneration, longitudinal plasma p-tau181 changes were associated with prospective cognitive decline in both CU (r = −0.24, P < .001) and Clmp (r = 0.34, P < .001) individuals. Plasma NFL changes were also associated with cognitive decline in CU (r = −0.12, P = .04) and Clmp (r = 0.30, P < .001) individuals. However, in a combined model with plasma p-tau181, the association in CU individuals was no longer significant for NFL, whereas in Clmp, longitudinal changes of both plasma markers were independently associated with variations in cognitive decline (CU: p-tau181, β = −0.23; 95% CI, −0.38 to −0.10; NFL, β = −0.04; 95% CI, −0.22 to 0.12; Clmp: p-tau181, β = 0.28; 95% CI, 0.17-0.39; NFL, β = 0.23; 95% CI, 0.10-0.38) (eFigure 18A in Supplement 1). Mediation analyses found that 25% to 45% of the plasma p-tau181 association with longitudinal cognition was mediated by changes in imaging-derived neurodegeneration markers (Figure 18B in Supplement 1).

The results of analyses stratified by Aβ status suggest that plasma p-tau181 changed in parallel with neurodegeneration.
Figure 1. Associations of Baseline Plasma Phosphorylated Tau at Threonine 181 (P-Tau181) and Neurofilament Light Chain (NfL) With Decreasing Glucose Metabolism and Increasing Atrophy

A Longitudinal hypometabolism, CU
- Plasma p-tau181
- Plasma NfL

B Longitudinal hypometabolism, Clmp
- Plasma p-tau181
- Plasma NfL

C Longitudinal atrophy, CU
- Plasma p-tau181
- Plasma NfL

D Longitudinal atrophy, Clmp
- Plasma p-tau181
- Plasma NfL

Regression lines displayed in graphs were computed by setting covariates in the linear model to average group levels (cognitively unimpaired [CU] or cognitively impaired [Clmp]) and categorical variables to the reference (female sex and, for atrophy measures, 3-T field strength). Age- and sex-adjusted associations of baseline plasma p-tau181 and NfL with hypometabolism progression are shown at the voxel (upper row) and Alzheimer disease (AD) meta-region of interest (ROI) level (bottom row) in cognitively unimpaired (A) and cognitively impaired (B) individuals. To account for the difference in sample sizes, results of voxelwise analyses were thresholded on the voxel level at \( P < .01 \) (uncorrected) for the CU group and at \( P < .001 \) (uncorrected) for Clmp. All maps were further thresholded at \( P < .05 \) (familywise error corrected) at the cluster level. The eTable in Supplement 1 shows ROI analyses using hippocampus volume. FDG indicates fluorine 18-labeled fluorodeoxyglucose; PET, positron emission tomography; and SUVR, standardized uptake value ratio.

Progression only among Aβ+ participants and in a spatial pattern that closely corresponds to AD-typical regional neurodegeneration, as evidenced by both voxelwise and ROI analyses (FDG PET SUVR change: Aβ+ Clmp, \( r = -0.27, P < .001 \); gray matter volume change: Aβ+ CU, \( r = -0.25, P = .02 \); Aβ+ Clmp, \( r = -0.25, P < .001 \)) (Figure 4; eFigure 19 in Supplement 1). Similarly, plasma p-tau181 changes accompanied cognitive decline in Aβ+ participants (Aβ+ CU: \( r = -0.30, P = .003 \); Aβ+ Clmp: \( r = 0.31, P < .001 \)) but not in Aβ− participants (Aβ− CU: \( r = -0.14, P = .05 \); Aβ− Clmp: \( r = -0.01, P = .92 \). By contrast, plasma NfL changes paralleled neurodegenerative changes also in Aβ− individuals, particularly with respect to progressive atrophy across widespread cortical areas that also covered large parts of the frontal lobe (eFigure 20 in Supplement 1). In ROI analyses, plasma NfL changes were associated with atrophy progression in AD-vulnerable ROIs for both Aβ groups, but associations with

Downloaded From: https://jamanetwork.com/ on 09/26/2023
Blood Phosphorylated Tau181, Neurofilament Light Chain, and Neurodegeneration in Alzheimer Disease

Figure 2. Associations of Baseline Plasma Phosphorylated Tau at Threonine 181 (P-Tau181) With Decreasing Glucose Metabolism and Increasing Atrophy in Amyloid-β-Positive (Aβ+) Cognitively Unimpaired and Impaired Participants

Associations of baseline plasma p-tau181 with longitudinal hypometabolism in Aβ+ cognitively unimpaired (CU) (A) and Aβ+ cognitively impaired (CImp) (B) and with longitudinal atrophy in Aβ+ CU (C) and Aβ+ CImp (D) at the voxel and region-of-interest (ROI) level. Models were adjusted for age, sex, and, for atrophy measures, for total intracranial volume and MRI field strength. Statistical maps were thresholded using a lenient threshold (P < .05 [uncorrected]) at the voxel level and further thresholded at the cluster level by restricting results to clusters with a number of voxels higher than the expected number of voxels as predicted using random field theory) to maximize detection power in the Aβ− group while keeping identical thresholds for the Aβ+ group. Reported partial correlation coefficients were adjusted for the same covariates. Regression lines were computed by setting covariates in the linear model to average group levels (CU or CImp) and categorical variables to the reference (female sex and, for atrophy measures, 3-T field strength). The eTable in Supplement 1 shows ROI analyses using hippocampus volume. FDG indicates fluorine 18-labeled fluorodeoxyglucose; SUVR, standardized uptake value ratio.

Discussion

In this cohort study, we investigated longitudinal associations of p-tau181 levels in blood with multimodal imaging biomarkers of regional neurodegeneration and cognition in ADNI participants covering the entire AD spectrum. Furthermore, we compared this novel AD biomarker with a blood-based biomarker of neuronal injury, plasma NfL, which is increased in several neurodegenerative disorders and thus not considered specific for AD.22 Our findings suggest that (1) baseline plasma p-tau181 levels were associated with cognitive decline as well as with concurrent and prospective neurodegeneration in areas typically vulnerable in AD, as measured by structural MRI and FDG PET; (2) longitudinal increments of plasma p-tau181 accompanied cognitive decline and longitudinal progression of neurodegeneration in the same AD-vulnerable regions; (3) plasma p-tau181 and NfL were independently associated with cognition and neurodegeneration in AD-vulnerable areas; (4) plasma p-tau181 was specifically associated with cognitive impairment and an AD-typical regional neurodegeneration pattern among participants in the AD continuum (Aβ+), whereas NfL was associated with cognitive decline and neurodegeneration in both Aβ+ and Aβ− groups, generally in spatial neurodegeneration patterns that were less specific for AD-vulnerable regions; and (5) the associations between plasma p-tau181 and cognition were not fully mediated by imaging-derived neurodegeneration markers, suggesting independent links between plasma p-tau181 and cognitive impairment that are not explained by neurodegeneration as assessed with neuroimaging. Taken together, these results suggest the potential of plasma p-tau181 as a scalable, cost-effective, and accessible tool for estimating and monitoring AD-specific disease progression, extending results from previous studies that mainly focused on the ability of plasma p-tau181 for establishing disease status.7,10-12

A main finding of the present study was the observation that longitudinal increments of plasma p-tau181 paralleled worsening hypometabolism, atrophy, and cognitive decline.
These associations, although generally stronger in the CImp group, were also significant in CU individuals, which suggests that plasma p-tau181 elevations might capture AD-related neurodegenerative processes even at early, presymptomatic disease stages and supports the use of repeated measurements of plasma p-tau181 biomarker levels over time for disease monitoring. However, some of the observed effect sizes were relatively small, particularly in the CU group. Thus, future studies are warranted to elucidate the clinical relevance of longitudinal plasma biomarkers for disease monitoring in different at-risk populations.

Our longitudinal findings resonate with recent results on longitudinal measures of plasma p-tau217, another novel candidate plasma biomarker of AD. Although the associations...
regions that are characteristically involved in AD-related
pometabolism and atrophy in specific temporoparietal brain
plasmap-tau181elevations were primarily associated with hy-
tive value of plasma p-tau181 when Aβ status information is
associations in the Aβ+ CU group, which suggests the predic-
tion in the CU group; however, we did observe more pronounced
els were weakly associated with prospective neurodegenera-
tau181 levelswereassociatedwithcurrentandfutureneuro-
higher than the expected number of voxels as predicted using random field
Using brainwide analyses at the voxel level, we found that plasma p-tau181 levels were weakly associated with prospective neurodegeneration in the CU group; however, we did observe more pronounced associations in the Aβ+ CU group, which suggests the predictive value of plasma p-tau181 when Aβ status information is available.

Using brainwide analyses at the voxel level, we found that plasma p-tau181 elevations were primarily associated with hypometabolism and atrophy in specific temporoparietal brain regions that are characteristically involved in AD-related neurodegeneration. and these associations were only present among Aβ+ individuals. Together, these findings suggest that p-tau181 is a specific marker for AD-related neurodegeneration. By contrast, plasma NfL was also significantly associated with hypometabolism and atrophy among Aβ− individuals, and these associations commonly covered larger frontoparietal areas not typically involved in AD. Neurodegeneration in frontoparietal areas has previously been found to be associated with white matter hyperintensities in aging, suggesting that the observed plasma NfL neurodegeneration patterns could be reflective of small vessel disease–related neuronal injury. Accordingly, plasma NfL levels have also been found to increase with increasing white matter hyperintensity burden. This finding is in line with findings from several previous studies indicating that plasma NfL is a more general marker of neuronal degeneration that is not specific for AD. Interestingly, in combined regression models, we found that both plasma markers were independently associated with neurodegeneration in AD–typical areas, which suggests that both provide unique information about the underlying neurodegenerative processes that occur during the natural course of AD. This finding also suggests the potential for the combined use of these biomarkers for an optimized assessment of progressive neurodegeneration.
In line with findings from previous studies, we observed that baseline plasma p-tau181 levels were associated with prospective cognitive decline. Here, we extended this previous knowledge by noting that longitudinal increases of plasma p-tau181 paralleled cognitive decline even in asymptomatic stages of AD, further supporting the notion that plasma p-tau181 might capture early pathologic changes in the AD cascade. Moreover, we also found that approximately 50% to 70% of the associations of plasma p-tau181 with cognition were not mediated by hypometabolism or atrophy, suggesting that plasma p-tau181 reflects pathologic processes that influence cognitive performance through partly independent pathways not captured by these established imaging markers of neurodegeneration. This finding likely corresponds to the accumulation of neurofibrillary tangle pathology, which has been previously found to independently contribute to cognitive impairment beyond hypometabolism and atrophy measures. However, in the current study, we could not confirm this hypothesis owing to the lack of concurrent tau PET scans and plasma p-tau181 measures in the ADNI cohort. Further studies are needed to elucidate how tau PET mediates the associations between plasma p-tau181 and cognition.

Together, these findings further support the use of plasma p-tau181 not only for determining disease status but also as a cost-effective and specific biomarker of disease progression in AD. Plasma p-tau181, alone or in combination with plasma NfL, might represent a suitable tool for assessing and monitoring AD progression in clinical settings before conducting more expensive or invasive confirmatory imaging or cerebrospinal fluid tests. Owing to their close association with AD-typical neurodegeneration and cognition, repeated plasma p-tau181 measurements over time might also be useful to identify rapidly progressing forms of the disease in clinical scenarios as well as to track treatment outcomes in disease-modifying trials. Further studies in real clinical settings are warranted to investigate how the use of plasma biomarkers may affect clinically relevant outcomes.

**Strengths and Limitations**
This study features several strengths and limitations. First, we used a large, prospective cohort with longitudinal plasma biomarker data, as well as measures of cognition and multimodal imaging markers of neurodegeneration over a relatively long follow-up time. Second, almost all participants in the study also underwent Aβ PET, which allowed us to confirm that plasma p-tau181 elevations specifically correlated with neurodegeneration in participants along the AD continuum. Third, all the participants also had plasma NfL measurements, allowing a head-to-head comparison of the neurodegenerative features associated with each of the plasma-derived biomarkers. The study has several principal limitations. First, the study used a single cohort derived from ADNI, which represents a rather selective population. Because the measurement of plasma p-tau181 has only recently been introduced, there currently exists, to our knowledge, no other comparably large cohort that could provide access to blood-derived measures of p-tau181 and NfL in combination with the detailed neuroimaging information from structural MRI, FDG PET, and Aβ PET that was analyzed in our study, thus limiting the possibility to replicate our findings in an independent cohort at this time. Still, the large study sample as well as the robustness of the results, with converging findings from 2 different imaging modalities for measuring neurodegeneration along with measures of cognitive decline, provide strong evidence in support of the potential of plasma p-tau181 for disease monitoring in AD. Second, only approximately 50% of the study participants had longitudinal FDG PET scans, which limited the statistical power to detect associations with a decline in glucose metabolism, particularly in the CU group. Third, study participants did not have available tau PET scans at the moment of plasma p-tau181 measurement. Fourth, the ADNI study recruits participants who are relatively devoid of vascular pathology. Recent evidence suggests that white matter damage associates with Aβ deposition, and therefore, given the strong dependence of plasma p-tau181 on Aβ, it is unclear how vascular pathology may affect our findings.

**Conclusions**
In conclusion, our findings suggest that both baseline levels and longitudinal changes in plasma p-tau181 levels were associated with prospective neurodegeneration and cognitive decline that can be described as characteristic for AD. Plasma NfL showed similarly pronounced associations with cognition and imaging markers of neurodegeneration, but, in contrast to plasma p-tau181, these associations were not AD specific. These findings support the combined use of plasma p-tau181 and NfL for improved prediction and monitoring of disease progression in AD.
Blood Phosphorylated Tau181, Neurofilament Light Chain, and Neurodegeneration in Alzheimer Disease

Original Investigation Research

Author Contributions: Dr Schöll had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Moscoso, Grothe, Ashton, Karikari, Zetterberg, Schöll.

Acquisition, analysis, or interpretation of data: Ashton, Karikari, Zetterberg, Grothe, Karikari, Lantero Rodríguez, Snellman, Suárez-Calvet, Blennow, Zetterberg, Schöll.

Statistical analysis: Moscoso, Karikari.

Obtained funding: Karikari, Blennow, Zetterberg, Schöll.

Writing the manuscript: All authors.

Critical revision of the manuscript for important intellectual content: Grothe, Ashton, Karikari, Lantero Rodríguez, Snellman, Suárez-Calvet, Blennow, Zetterberg, Schöll.

Drafting of the manuscript: Moscoso, Ashton, Karikari.

Conflict of Interest Disclosures: Dr Zetterberg reported receiving grants from the Wallenberg Foundation, European Research Council, Swedish State Support for Clinical Research, Alzheimer Drug Discovery Foundation, and UK Dementia Research Institute at University College London; serving on the scientific advisory boards for Denal, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pintose Therapeutics, and Cogbio; giving lectures in symposia sponsored by Fujirebio, Alzceure, and Biogen, and cofounding Brain Biomarker Solutions in Gothenburg AB, which is a part of the GU Ventures Incubator Program, outside the submitted work. Dr Blennow reported serving as a consultant, on advisory boards, or at data monitoring committees for Abcam, Axon, Biogen, JOMDD/Shimadzu, Julius Clinical, Lilly, MagQu, Novartis, Roche Diagnostics, and Siemens Healthineers; and cofounding Brain Biomarker Solutions in Gothenburg AB, which is a part of the GU Ventures Incubator Program, outside the submitted work. Dr Suárez-Calvet reported giving lectures in symposia sponsored by Roche Diagnostics, S.L.U, outside the submitted work. Dr Schöll reported serving on a scientific advisory board for Servier outside the submitted work. No other disclosures were reported.

Funding/Support: This work was supported by the “Miguel Server” program grant CP19/00313 of the Spanish Instituto de Salud Carlos III (Dr Grothe); research fellowship A2020F012F from the Brightfocus Foundation, grant AF-930627 from the Swedish Alzheimer Foundation, grant FO2020-0240 from the Swedish Brain Foundation, grant 2020-00124 from the Ageneta Prytz-Folkes & Gösta Folkes Foundation, and support from the Swedish Dementia Foundation, the Aina (Ann) Wallströms and Mary-Ann Sjöbloms Foundation, the Anna Lisa and Brother Björnsson’s Foundation, Gmina Tjänarinnor, and the Gun and Bertil Stohnes Foundation (Dr Karikari); the Paolo Foundation and the Orion Research Foundation (Dr Schildman); grant 752130 from the European Union’s Horizon 2020 Research and Innovation Program under the Marie Skłodowska-Curie action grant agreement, grant P19/D055 from the Instituto de Salud Carlos III, and grant U2018-037478-I from the Spanish Ministry of Science, Innovation and Universities (Juan de la Cierva Programme) (Dr Suárez-Calvet); grant 2018-02532 from the Swedish Research Council, 681712 from the European Research Council, ALFGGB-720980 from the Swedish State Support for Clinical Research, 2018-09-2016662 from the Alzheimer Drug Discovery Foundation USA, and the UK Dementia Research Institute at University College London (Dr Zetterberg); grant 2017-00915 from the Swedish Research Council, RDAPB-2018-09-2016665 from the Alzheimer Drug Discovery Foundation USA, AF-742881 from the Swedish Alzheimer Foundation, FO2017-0243 from Hjälmfunden, Sweden, the Swedish state under the agreement between the Swedish government and the County Councils, ALFGGB-715986 from the ALF-agreement, and JPND2019-466-236 from the European Union Joint Program for Neurodegenerative Disorders (Dr Blennow); KAW 2014.0363 from the Knut and Alice Wallenberg Foundation (Wallenberg Centre for Molecular and Translational Medicine, 2017-02869 from the Swedish Research Council, ALFGGB-813971 from the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement, and AF-740193 from the Swedish Alzheimer Foundation (Dr Schöll). Data collection and sharing for this project was funded by the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (grant AG024904 and Department of Defense ADNI (grant W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc; Biogen; Bristol-Myers Squibb Company; Ceregene, Inc; Cogstate; Eisai Inc; Eli Lilly and Company; Euroimmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc; Fujirebio; GE Healthcare; IXICO Ltd; Janssen Alzheimer Immunotherapy Research & Development, LLC; Johnson & Johnson Pharmaceutical Research & Development LLC; Luminosity; Lundbeck; Merck & Co Inc; Mesoscale Diagnostics, LLC; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.

Role of the Funder/Sponsor: No role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Additional Contributions: Data used in preparation of this article were obtained from the ADNI database (adni.loni.usc.edu). As such, the investigators within ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in the analysis or the writing of this report.

Group Information: The ADNI investigators are listed in Supplement 2.

REFERENCES

Amyloid and Tau


